Crossmark

Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment

Crossref DOI link: https://doi.org/10.1007/s40261-019-00837-x

Published Online: 2019-08-21

Published Print: 2019-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sidharta, Patricia N.

Ulč, Ivan

Dingemanse, Jasper
Funding

Funding for this research was provided by:

Actelion Pharmaceuticals
License Information

Text and Data Mining valid from 2019-08-21

Version of Record valid from 2019-08-21
More Information

Article History

First Online: 21 August 2019

Compliance with Ethical Standards

:

: The study (NCT03165071) followed the principles of the Declaration of Helsinki and good clinical practice, and the protocol and its amendment were approved by an Independent Ethics Committee (Etická komise CEPHA s.r.o., Pilsen, Czech Republic) as well as by the National Health Authority of the Czech Republic. The study was conducted at CEPHA s.r.o, Pilsen, Czech Republic. All subjects provided written informed consent prior to screening.

: JD is a fellow of the American College of Clinical Pharmacology. PNS and JD are current employees of Idorsia Pharmaceuticals Ltd and former employees of Actelion Pharmaceuticals Ltd. IU was the principal investigator of the study that was sponsored by Actelion Pharmaceuticals Ltd. The authors report no other conflicts of interest in this work.

: The study was funded by Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.

Document is current

Any future updates will be listed below